- Home
- VSTM vs RGNX Comparison
VSTM vs RGNX Comparison
Compare VSTM & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- RGNX
- Stock Information
- Founded
- VSTM 2010
- RGNX 2008
- Country
- VSTM United States
- RGNX United States
- Employees
- VSTM N/A
- RGNX N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VSTM Health Care
- RGNX Health Care
- Exchange
- VSTM Nasdaq
- RGNX Nasdaq
- Market Cap
- VSTM 581.6M
- RGNX 661.2M
- IPO Year
- VSTM 2012
- RGNX 2015
- Fundamental
- Price
- VSTM $10.71
- RGNX $13.31
- Analyst Decision
- VSTM Strong Buy
- RGNX Strong Buy
- Analyst Count
- VSTM 9
- RGNX 7
- Target Price
- VSTM $13.38
- RGNX $30.29
- AVG Volume (30 Days)
- VSTM 2.8M
- RGNX 581.1K
- Earning Date
- VSTM 11-04-2025
- RGNX 11-06-2025
- Dividend Yield
- VSTM N/A
- RGNX N/A
- EPS Growth
- VSTM N/A
- RGNX N/A
- EPS
- VSTM N/A
- RGNX N/A
- Revenue
- VSTM $13,379,000.00
- RGNX $161,318,000.00
- Revenue This Year
- VSTM $88.60
- RGNX $198.02
- Revenue Next Year
- VSTM $416.99
- RGNX $2.67
- P/E Ratio
- VSTM N/A
- RGNX N/A
- Revenue Growth
- VSTM 33.79
- RGNX 91.30
- 52 Week Low
- VSTM $3.46
- RGNX $5.04
- 52 Week High
- VSTM $11.25
- RGNX $13.93
- Technical
- Relative Strength Index (RSI)
- VSTM 65.97
- RGNX 66.08
- Support Level
- VSTM $7.29
- RGNX $10.76
- Resistance Level
- VSTM $10.45
- RGNX $12.05
- Average True Range (ATR)
- VSTM 0.68
- RGNX 0.80
- MACD
- VSTM 0.23
- RGNX 0.17
- Stochastic Oscillator
- VSTM 93.53
- RGNX 87.42
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.